Metastatic colorectal cancer Clinical Trials

Recruiting metastatic colorectal cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat metastatic colorectal cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting metastatic colorectal cancer studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting metastatic colorectal cancer trials

Within

Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer

for Phase II

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07720115·Phase 2

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

for Metastatic Colorectal Cancer

Sponsor: UNICANCER

Sex: All·Age: 18+

Code: NCT07359456·Phase 2

Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer

for Colorectal Cancer

1 site in St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT07662031·Phase 2

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

for Metastatic Colorectal Cancer

1 site in Omaha

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT07416552·Phase 1

A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland

for Metastatic Colorectal Cancer

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07623174

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

for Dynamic Tumor Resistance

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07318389·EARLY_Phase 1

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

for Metastatic Colorectal Cancer

1 site in New York

Sponsor: Dan Feng

Sex: All·Age: 18+

Code: NCT07277322·Phase 1, Phase 2

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

for Metastatic Colorectal Cancer

6 sites incl. Peoria

Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All·Age: 18+

Code: NCT07549412·Phase 3

Apply to this trial

JS212 Combination Therapies in Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07503756·Phase 2

Apply to this trial

Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

for Metastatic Colorectal Cancer

Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd.

Sex: All·Age: 18+

Code: NCT07314294·Phase 2

Apply to this trial

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

for Metastatic Colorectal Cancer

Sponsor: CuraCell TX AB

Sex: All·Age: 18+

Code: NCT07255664·Phase 1, Phase 2

Apply to this trial

A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.

for Metastatic Colorectal Cancer

Sponsor: Boryung Pharmaceutical Co., Ltd

Sex: All·Age: 19+

Code: NCT07263178

Apply to this trial

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: The First Hospital of Jilin University

Sex: All·Age: 18 - 75

Code: NCT07559760·Phase 2

Apply to this trial

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

for Metastatic Colorectal Cancer

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Sex: All·Age: 18+

Code: NCT06856837·Phase 2

Apply to this trial

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

for Metastatic Colorectal Cancer

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Sex: All·Age: 18+

Code: NCT07071844·Phase 2

Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Sex: All·Age: 18 - 75

Code: NCT07718490·Phase 2

Apply to this trial

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Qilu Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07025239·Phase 3

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT06959550·Phase 2

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

for Metastatic Colorectal Cancer

4 sites incl. New Haven

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07079631·Phase 1, Phase 2

Apply to this trial

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

for Advanced Colorectal Cancer

1 site in Birmingham

Sponsor: University of Alabama at Birmingham

Sex: All·Age: 19+

Code: NCT06867822·Phase 1

Apply to this trial

Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie

for Metastatic Colorectal Cancer

Sponsor: Libbs Farmacêutica LTDA

Sex: All·Age: 18+

Code: NCT06808685

Apply to this trial

Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Swiss Cancer Institute

Sex: All·Age: 18+

Code: NCT07617610

Apply to this trial

Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)

for Tumor, Colorectal

Sponsor: St. Olavs Hospital

Sex: All·Age: 18+

Code: NCT06907342·Phase 2

Apply to this trial

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

for Metastatic Colorectal Cancer

Sponsor: University of Saskatchewan

Sex: All·Age: 18 - 70

Code: NCT03401294·Phase 2

Apply to this trial

Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Liu Huang

Sex: All·Age: 18+

Code: NCT06980532·Phase 1, Phase 2

Apply to this trial

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

14 sites incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06820463·Phase 2

Apply to this trial

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

for Metastatic Colorectal Cancer

Sponsor: R-Pharm

Sex: All·Age: 18+

Code: NCT07543744·Phase 1

Apply to this trial

Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sex: All·Age: 18 - 75

Code: NCT06858969·Phase 2

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

for Metastatic Colorectal Cancer

1 site in Tampa

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All·Age: 18+

Code: NCT06553885·Phase 2

Apply to this trial

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

for Metastatic Colorectal Cancer

Sponsor: UNICANCER

Sex: All·Age: 18+

Code: NCT06245356·Phase 2

Apply to this trial

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

for Metastatic Colorectal Cancer

11 sites incl. Scottsdale

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06792695·Phase 2

Apply to this trial

A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: The First Hospital of Jilin University

Sex: All·Age: 18 - 75

Code: NCT06979908·Phase 2

Apply to this trial

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

for Metastatic Colorectal Cancer

2 sites incl. Newark

Sponsor: Riboscience, LLC.

Sex: All·Age: 18+

Code: NCT06824064·Phase 2

Apply to this trial

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

for Solid Tumor, Adult

19 sites incl. Duarte

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06625775·Phase 1

Apply to this trial

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

for Metastatic Colorectal Cancer

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT06493760·Phase 2

Apply to this trial

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

for Metastatic Colorectal Cancer

2 sites incl. Boston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT06412198·Phase 1, Phase 2

Apply to this trial

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

for Metastatic Colorectal Cancer

Sponsor: Liu Huang

Sex: All·Age: 18 - 75

Code: NCT06551207

Apply to this trial

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: West China Hospital

Sex: All·Age: 18 - 85

Code: NCT06341309·Phase 1, Phase 2

FAPI Molecular Imaging for Diagnosis of the CMS4 Unfavorable Colorectal Cancer Subtype

for Metastatic Colorectal Cancer

Sponsor: UMC Utrecht

Sex: All·Age: 18+

Code: NCT06191120

Apply to this trial

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

for Metastatic Colorectal Cancer

Sponsor: Fudan University

Sex: All·Age: 18+

Code: NCT06513221·Phase 2

Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial

for Colorectal Cancer

1 site in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18 - 50

Code: NCT06202183

Apply to this trial

Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

for Metastatic Colorectal Cancer

Sponsor: Centre Hospitalier Universitaire de Besancon

Sex: All·Age: 18+

Code: NCT06425133·Phase 2

Apply to this trial

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

for Metastatic Colorectal Cancer

14 sites incl. Chandler

Sponsor: Amgen

Sex: All·Age: 18+

Code: NCT06252649·Phase 3

Apply to this trial

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: West China Hospital

Sex: All·Age: 18 - 85

Code: NCT06341296·Phase 2

Apply to this trial

FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: UMC Utrecht

Sex: All·Age: 18+

Code: NCT06563986·Phase 2

Apply to this trial

Combination Therapy for BRAF-V600E Metastatic CRCm

for Metastatic Colorectal Cancer

Sponsor: Vall d'Hebron Institute of Oncology

Sex: All·Age: 18+

Code: NCT06411600·Phase 2

Apply to this trial

Sacituzumab Govitecan in Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: University Hospital Heidelberg

Sex: All·Age: 18+

Code: NCT06243393·Phase 2, Phase 3

Apply to this trial

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

for Metastatic Colorectal Cancer

1 site in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06149481·Phase 1, Phase 2

Apply to this trial

A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)

for Metastatic Colorectal Cancer

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Sex: All·Age: 18+

Code: NCT06195111

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

for RAS Mutation

Sponsor: Beijing Hospital

Sex: All·Age: 18+

Code: NCT06321081·Phase 2

Apply to this trial

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

for Metastatic Colorectal Cancer

Sponsor: First Affiliated Hospital of Wenzhou Medical University

Sex: All·Age: 18 - 75

Code: NCT06485713·Phase 2

Apply to this trial

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

for Metastatic Colorectal Cancer

Sponsor: Alethia Biotherapeutics

Sex: All·Age: 18+

Code: NCT06225843·Phase 2

Apply to this trial

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

for CRC

Sponsor: Zhejiang Cancer Hospital

Sex: All·Age: 18 - 85

Code: NCT06195670·Phase 1, Phase 2

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

for Metastatic Colorectal Cancer

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT05985954·Phase 1

Apply to this trial

ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

for Metastatic Colorectal Cancer

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Sex: All·Age: 18+

Code: NCT05787197

Apply to this trial

Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Fudan University

Sex: All·Age: 18 - 75

Code: NCT06218810·Phase 2

Apply to this trial

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

Sex: All·Age: 18 - 75

Code: NCT06776757·Phase 1, Phase 2

Apply to this trial

MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases

for Metastatic Colorectal Cancer

Sponsor: Shengjing Hospital

Sex: All·Age: 18 - 80·Accepts healthy volunteers

Code: NCT06208397

Apply to this trial

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sex: All·Age: 18 - 80

Code: NCT06543836·Phase 2

Apply to this trial

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer

Sponsor: Sun Yat-sen University

Sex: All·Age: 18+

Code: NCT05959356·Phase 2

Apply to this trial

Metastatic colorectal cancer clinical trials — common questions

Are metastatic colorectal cancer clinical trials free to join?

Yes. Participating in a metastatic colorectal cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a metastatic colorectal cancer clinical trial?

Each metastatic colorectal cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a metastatic colorectal cancer trial near me?

Use the location controls above. We'll show recruiting metastatic colorectal cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many metastatic colorectal cancer trials are recruiting right now?

We're currently tracking roughly 21 recruiting metastatic colorectal cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Metastatic colorectal cancer trials by city

Birmingham, AL Boston, MA Duarte, CA Madison, WI Newark, DE Omaha, NE Peoria, IL Tampa, FL

Related specialties

Oncology GI oncology